Pharmacokinetic and technical comparison of Sandostatin ® LAR ® and other formulations of long-acting octreotide
2011
Background
Sandostatin® LAR® (Novartis Pharma AG) is a long-acting repeatable formulation of the somatostatin analogue octreotide, the safety and efficacy of which has been established through 15 years of clinical experience. Recently, other formulations of octreotide using polymer poly(lactic-co-glycolic acid) technology have been developed. This study compares the composition and pharmacokinetic (PK) profile of Sandostatin LAR with three other versions of the depot delivery system (formulations A, B and C, available in selected countries).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
12
References
24
Citations
NaN
KQI